Budget Impact Analysis of the Introduction of New Therapeutic Agents for the Treatment of Metastatic Castration Resistant Prostate Cancer (MCRPC) Patients After Docetaxel Failure in the Brazilian Private Health System

Authors :: V. Vitale
E. Asano
Source :: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 17(7)
Publication Year :: 2016

Subjects :: Oncology
medicine.medical_specialty
business.industry
Health Policy
MEDLINE
Public Health, Environmental and Occupational Health
Budget impact
Castration resistant
medicine.disease
Prostate cancer
Docetaxel
Internal medicine
Medicine
business
health care economics and organizations
medicine.drug

ISSN :: 15244733
Volume :: 17
Issue :: 7
Database :: OpenAIRE
Journal :: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Accession number :: edsair.doi.dedup.....0d44463e4cbbd2c0fa56dd8a3a4522bd

Tools